Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Cardiol Therapeutics Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: Cardiol Therapeutics Inc.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: Cardiol Therapeutics Inc.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Cardiol Therapeutics Inc. SectorCanada

Fundamentals

-

Growth

Revenue growth

-

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings

Rating Valuation

Cardiol Therapeutics Inc. SectorCanada

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Cardiol Therapeutics Inc. SectorCanada

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Cardiol Therapeutics Inc. SectorCanada

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Cardiol Therapeutics Inc. SectorCanada

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
176M - - - -
48.72B
AAA
43.99B -
B
- -
40.82B -
39.79B
AAA
32.7B
A
16.66B
BBB
16.84B - - - -
13.95B
AA
13.58B
AA
Average 26.72B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Ratings Cardiol Therapeutics Inc.